lapatinib has been researched along with ketanserin in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (ketanserin) | Trials (ketanserin) | Recent Studies (post-2010) (ketanserin) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 3,094 | 335 | 283 |
| Protein | Taxonomy | lapatinib (IC50) | ketanserin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0016 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0021 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | 0.265 | |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | 6.5 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0184 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0027 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0016 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.29 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 1.8 | |
| Synaptic vesicular amine transporter | Homo sapiens (human) | 0.18 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Bansal, R; Malhotra, A | 1 |
1 review(s) available for lapatinib and ketanserin
| Article | Year |
|---|---|
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines | 2021 |
1 other study(ies) available for lapatinib and ketanserin
| Article | Year |
|---|---|
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |